Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 659 results for position

  1. Galcanezumab for preventing migraine (TA659)

    Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.

  2. Tildrakizumab for treating moderate to severe plaque psoriasis (TA575)

    Evidence-based recommendations on tildrakizumab (Ilumetri) for treating moderate to severe plaque psoriasis in adults.

  3. Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer (TA403)

    Evidence-based recommendations on ramucirumab (Cyramza) for locally advanced or metastatic non-small-cell lung cancer in adults who have had platinum-based chemotherapy.

  4. Vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions (IPG774)

    Evidence-based recommendations on vaginal transluminal endoscopic hysterectomy and adnexal surgery for benign gynaecological conditions. This involves removing the uterus (womb), and sometimes the fallopian tubes and ovaries, through the vagina.

  5. Sherlock 3CG Technology for PICC placement, how it has helped to develop a vascular access service at Medway Maritime NHS Foundation Trust

    placed with the Site Rite 5 and netbook to compare tip position on chest x ray with tip position with 3CG technology. The...

  6. Botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention (IPG766)

    Evidence-based recommendations on botulinum toxin type A injections into the urethral sphincter for idiopathic chronic non-obstructive urinary retention. This involves injecting botulinum toxin type A into the urethral sphincter.

  7. Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)

    Evidence-based recommendations on upadacitinib (Rinvoq) for treating active non-radiographic axial spondyloarthritis in adults.

  8. Durvalumab for maintenance treatment of unresectable non-small-cell lung cancer after platinum-based chemoradiation (TA798)

    Evidence-based recommendations on durvalumab (Imfinzi) for locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation in adults.

  9. Knowledge transfer seminars

    Learn from NICE International, part of the UK’s National Institute for Health and Care Excellence, about how to improve your nation’s health and wellbeing

  10. Retrobulbar irradiation for thyroid eye disease (IPG148)

    Evidence-based recommendations on retrobulbar irradiation for thyroid eye disease. This involves using radiation to target the tissue behind the eyeball and reduce inflammation.

  11. Percutaneous endoscopic colostomy (IPG161)

    Evidence-based recommendations on percutaneous endoscopic colostomy. This involves placing a plastic tube in the bowel that runs back through a small opening in the abdomen to allow waste to pass through to a drainage bag worn outside the body.

  12. Memokath-028, 044 and 045 stents for urethral obstruction (MIB123)

    NICE has developed a medtech innovation briefing (MIB) on Memokath-028, 044 and 045 stents for urethral obstruction .

  13. Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia (TA393)

    Evidence-based recommendations on alirocumab (Praluent) for treating primary hypercholesterolaemia or mixed dyslipidaemia in adults.

  14. Romiplostim for the treatment of chronic immune thrombocytopenia (TA221)

    Evidence-based recommendations on romiplostim (Nplate) for treating chronic immune thrombocytopenia in adults.

  15. Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts (TA399)

    Evidence-based recommendations on azacitidine (Vidaza) for treating acute myeloid leukaemia with more than 30% bone marrow blasts.